{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:16:57Z","timestamp":1787066217309,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,7,1]]},"DOI":"10.1093\/humrep\/15.7.1490","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:22:29Z","timestamp":1027707749000},"page":"1490-1498","source":"Crossref","is-referenced-by-count":292,"title":["Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial"],"prefix":"10.1093","volume":"15","author":[{"name":"The European Orgalutran\u00ae Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mannaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,7]]},"reference":[{"key":"key\n\t\t\t\t20180328182237_ALBANO-ETAL-1997","unstructured":"Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 67, 917\u2013922."},{"key":"key\n\t\t\t\t20180328182237_ALBANO-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Albano, C., Smitz, J., Tournaye H. et al. (1999) Luteal phase and clinical outcome after human menopausal gonadotrophin\/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization\/intracytoplasmic sperm injection cycles. Hum. Reprod., 14, 1426\u20131430.","DOI":"10.1093\/humrep\/14.6.1426"},{"key":"key\n\t\t\t\t20180328182237_BRUS-ETAL-1997","unstructured":"Brus, L., Lambalk, C.B., de Koning J. et al. (1997) Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum. Reprod., 12, 769\u2013773."},{"key":"key\n\t\t\t\t20180328182237_COCHRAN-1954","doi-asserted-by":"crossref","unstructured":"Cochran, W. (1954) The combination of estimates from different experiments. Biometrics, 10, 101\u2013129.","DOI":"10.2307\/3001666"},{"key":"key\n\t\t\t\t20180328182237_CRAMER-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Cramer, D.W., Powers, D.R., Oskowitz, S.P. et al. (1999) Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Fertil. Steril., 72, 83\u201389.","DOI":"10.1016\/S0015-0282(99)00187-9"},{"key":"key\n\t\t\t\t20180328182237_DE-JONG-ETAL-1998","doi-asserted-by":"crossref","unstructured":"De Jong, D., Macklon, N.S., Mannaerts B. et al. (1998) High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum. Reprod., 13, 573\u2013575.","DOI":"10.1093\/humrep\/13.3.573"},{"key":"key\n\t\t\t\t20180328182237_DIEDRICH-ETAL-1994","unstructured":"Diedrich, K., Diedrich, C., Santos, E. et al. (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum. Reprod., 9, 788\u2013791."},{"key":"key\n\t\t\t\t20180328182237_FELBERBAUM-1999","unstructured":"Felberbaum, R. (1999) Cetrorelix in controlled ovarian stimulation for ART: results of phase III, multiple dose treatment. Gynecol. Endocrinol., 13, Abstract 028."},{"key":"key\n\t\t\t\t20180328182237_FELBERBAUM-ETAL-1995","unstructured":"Felberbaum, R., Reissman, T.K., Kupker, W. et al. (1995) Preserved pituitary response under ovarian stimulation with HMG and GnRH-antagonists (Cetrorelix) in women with tubal infertility. Eur. J. Obstet. Gynecol. Reprod. Biol., 61, 151\u2013155."},{"key":"key\n\t\t\t\t20180328182237_FILICORI-ETAL-1986","unstructured":"Filicori, M., Santoro, N., Merriam, G.R. et al. (1986) Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J. Clin. Endocrinol. Metab., 62, 1136\u20131144."},{"key":"key\n\t\t\t\t20180328182237_FRYDMAN-ETAL-1988","doi-asserted-by":"crossref","unstructured":"Frydman, R., Belaisch-Allert, J., Parneix, I. et al. (1988) Comparison between flare-up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program. Fertil. Steril., 50, 471\u2013475.","DOI":"10.1016\/S0015-0282(16)60135-8"},{"key":"key\n\t\t\t\t20180328182237_FUJIMOTO-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Fujimoto, V.Y., Monroe, S.E., Nelson, L.R. et al. (1997) Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (ganirelix) administered by intranasal spray. Fertil. Steril., 67, 469\u2013473.","DOI":"10.1016\/S0015-0282(97)80071-4"},{"key":"key\n\t\t\t\t20180328182237_GANIRELIX-DOSE-FINDING-STUDY-GROUP-1998","unstructured":"Ganirelix dose-finding study group (1998) A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH-antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone. Hum. Reprod., 13, 3023\u20133031."},{"key":"key\n\t\t\t\t20180328182237_GORDON-ETAL-1990","unstructured":"Gordon, K., Danforth, D.R., Williams, R.F. et al. (1990) A novel regimen of gonadotrophin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotrophin secretion and ovulation induction. Fertil. Steril., 54, 1140\u20131145."},{"key":"key\n\t\t\t\t20180328182237_IKEDA-ETAL-1997","unstructured":"Ikeda, M., Taga, M., Kurogi, K. and Minaguchi, H. (1997) Gene expression of gonadotrophin-releasing hormone, but not its receptor, in human endometrium and decidua. Mol. Endocrinol., 135, 165\u2013168."},{"key":"key\n\t\t\t\t20180328182237_ITSKOVITZ-ETAL-1991","unstructured":"Itskovitz, J., Boldes, R., Levron, J. et al. (1991) Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril., 56, 213\u2013220."},{"key":"key\n\t\t\t\t20180328182237_ITSKOVITZ-ELDOR-ETAL-1998","unstructured":"Itskovitz-Eldor, J., Kol, S., Mannaerts, B. and Coelingh Bennink, H. (1998) First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and GnRH antagonist ganirelix (Org 37462). Hum. Reprod., 13, 294\u2013295."},{"key":"key\n\t\t\t\t20180328182237_KOL-ETAL-1999","unstructured":"Kol, S., Lightman, A., Hillensjo\u0308, T. et al. (1999) High doses of GnRH antagonist in IVF do not adversely effect the outcome of subsequent freeze\u2013thaw cycles. Hum. Reprod., 14, 2242\u20132444."},{"key":"key\n\t\t\t\t20180328182237_LATOUCHE-ETAL-1989","doi-asserted-by":"crossref","unstructured":"Latouche, J., Crumerolle-Arias, M., Jordan, D. et al. (1989) GnRH receptors in human granulosa cells: anatomical localization and characterization autoradiographic study. Endocrinology, 125, 1739\u20131741.","DOI":"10.1210\/endo-125-3-1739"},{"key":"key\n\t\t\t\t20180328182237_LIU-ETAL-1992","unstructured":"Liu, H.C., Lai, Y.M., Davis, O. et al. (1992) Improved pregnancy outcome with gonadotrophin-releasing hormone agonist (GnRHa) stimulation is due to improvement in oocytes quantity rather than quality. J. Assist. Reprod. Genet., 9, 338\u2013344."},{"key":"key\n\t\t\t\t20180328182237_LOUMAYE-1990","doi-asserted-by":"crossref","unstructured":"Loumaye, E. (1990) The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum. Reprod., 5, 357\u2013376.","DOI":"10.1093\/oxfordjournals.humrep.a137105"},{"key":"key\n\t\t\t\t20180328182237_LOUMAYE-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Loumaye, E., Engrand, P., Howles, C. and O'Dea, L. (1997) Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil. Steril., 67, 889\u2013899.","DOI":"10.1016\/S0015-0282(97)81402-1"},{"key":"key\n\t\t\t\t20180328182237_MINARETZIS-ETAL-1995","unstructured":"Minaretzis, D., Alper, M.M., Oskowitz, S.P. et al. (1995) Gonadotrophin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyper-stimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am. J. Obstet. Gynecol., 172, 1518\u20131525."},{"key":"key\n\t\t\t\t20180328182237_NELSON-ETAL-1995","unstructured":"Nelson, L.R., Fujimoto, V.Y., Jaffe R.B. et al. (1995) Suppression of follicular phase pituitary-gonadal function by a potent new gonadotrophin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil. Steril., 63, 963\u2013969."},{"key":"key\n\t\t\t\t20180328182237_OBERYE-ETAL-1999A","doi-asserted-by":"crossref","unstructured":"Oberye\u0301, J.J.L., Mannaerts, B.M.J.L., Kleijn, H.J. and Timmer, C.J. (1999a) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran): Part I. Absolute bioavailability of 0.25 mg ganirelix after single subcutaneous injection in healthy female volunteers. Fertil. Steril., 72, 1001\u20131005.","DOI":"10.1016\/S0015-0282(99)00413-6"},{"key":"key\n\t\t\t\t20180328182237_OBERYE-ETAL-1999B","doi-asserted-by":"crossref","unstructured":"Oberye\u0301, J.J.L., Mannaerts, B.M.J.L., Huisman, J.A.M. and Timmer, C.J. (1999b) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran): Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil. Steril., 72, 1006\u20131012.","DOI":"10.1016\/S0015-0282(99)00414-8"},{"key":"key\n\t\t\t\t20180328182237_OLIVENNES-ETAL-1996","unstructured":"Olivennes, F., Fanchin, R., Bouchard, P. et al. (1996) Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil. Steril., 66, 151\u2013153."},{"key":"key\n\t\t\t\t20180328182237_ORTMANN-ETAL-1999","unstructured":"Ortmann, O., Weiss, J.M., Gurke, E.M. et al. (1999) Ovarian effects of GnRH antagonists. Gynecol. Endocrinol., 13, Abstract 102."},{"key":"key\n\t\t\t\t20180328182237_OUT-ETAL-1995","unstructured":"Out, H.J., Mannaerts, B.M.J.L., Driessen, S.G.A.J. et al. (1995) A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod., 10, 2534\u20132540."},{"key":"key\n\t\t\t\t20180328182237_RABINOVICI-ETAL-1992","unstructured":"Rabinovici, J., Rothman, P., Monroe, S.E. et al. (1992) Endocrine effects and pharmacokinetic characteristics of a potent new gonadotrophin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J. Clin. Endocrinol. Metab., 75, 1220\u20131225."},{"key":"key\n\t\t\t\t20180328182237_RAGA-ETAL-1998","unstructured":"Raga, F., Casan, E.M., Kruessel, J.S. et al. (1998) Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol. Reprod., 59, 661\u2013669."},{"key":"key\n\t\t\t\t20180328182237_TAN-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Tan, S.L., Kingsland, C., Campbell, S. et al. (1992) The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil. Steril., 57, 810\u2013814.","DOI":"10.1016\/S0015-0282(16)54963-2"},{"key":"key\n\t\t\t\t20180328182237_TREASURE-AND-MACRAE-1999","unstructured":"Treasure, T. and MacRae, K.D. (1999) Minimisation: the platinum standard for trials? Br. Med. J., 317, 362\u2013363."},{"key":"key\n\t\t\t\t20180328182237_VERBOST-ETAL-1999","unstructured":"Verbost, P.M, Smitz, J., Peddemors, C. et al. (1999) Effects of GnRH-agonist and antagonists on steroid production in rat and human granulosa cells. Gynecol. Endocrinol., 13, Abstract 101."},{"key":"key\n\t\t\t\t20180328182237_WHITEHEAD-AND-WHITEHEAD-1991","unstructured":"Whitehead, A. and Whitehead, J. (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat. Med., 10, 1665\u20131677."}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/15\/7\/1490\/11529021\/0151490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T03:21:05Z","timestamp":1583292065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/15\/7\/1490\/2915322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2000,7]]},"published-print":{"date-parts":[[2000,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/15.7.1490","relation":{},"ISSN":["1460-2350","0268-1161"],"issn-type":[{"value":"1460-2350","type":"electronic"},{"value":"0268-1161","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,7]]},"published":{"date-parts":[[2000,7,1]]}}}